ECONOMIC IMPACT OF BIMEKIZUMAB FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN FRANCE
Author(s)
Gérard André De Pouvourville, PhD1, Mourad Lahfa, MD2, Esther Fabre, MSc, PharmD3, Yoann Neau, PharmD3, Tanguy Pieplu, MSc4, Laetitia Rey, PharmD4, Chloe Gerves-Pinquie, PhD4, Jérémy Gottlieb, MD5.
1ESSEC BUSINESS SCHOOL, Paris, France, 2Cabinet Médical Privé, Biarritz, France, 3UCB Pharma SA, Courbevoie, France, 4IQVIA, Paris, France, 5Centre hospitalier de Niort, Niort, France.
1ESSEC BUSINESS SCHOOL, Paris, France, 2Cabinet Médical Privé, Biarritz, France, 3UCB Pharma SA, Courbevoie, France, 4IQVIA, Paris, France, 5Centre hospitalier de Niort, Niort, France.
OBJECTIVES: This study aimed to assess the budget impact of introducing bimekizumab, a humanized monoclonal immunoglobulin (Ig)-G1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, for the treatment of moderate to severe Plaque Psoriasis in France.
METHODS: A 5-year budget impact model was developed to estimate the economic impact of bimekizumab’s introduction into the therapeutic strategy, from a societal perspective. All relevant comparators (anti-tumor necrosis factor (TNF)-alpha, anti-IL-17, anti-IL-12/23, anti-IL-23 and anti-phosphodiesterase (PDE)-4) were included in the analysis. The main market shares uptake assumption was a gain of bimekizumab over anti-IL-17 and anti-IL-23 treatments which have a similar therapeutic class, from 5% in year 1 to 11.6% in year 5. Psoriasis Area and Severity Index (PASI) 100 responses at 52 weeks from a published network meta-analysis, and adverse events incidence from clinical trials and products characteristics were considered. The target population assessed by the French Health Authority was integrated. Direct medical costs were estimated using French databases, including treatment acquisition based on list prices and considering biosimilars when available, administration, monitoring, and adverse events management. Productivity losses were derived from the literature, valued using the mean salary in France and applied to patients not achieving PASI 100.
RESULTS: In the eligible population of 77,350 patients, introducing bimekizumab resulted in total societal cost savings of €35,433,778 over 5 years, mainly driven by a reduction in productivity losses (95%). These savings correspond to a 0.61% decrease in the overall societal expenses associated with plaque psoriasis, estimated at €5,815,046,725. After the first year, annual treatment acquisition costs are reduced by bimekizumab’s inclusion, impacting the health insurance budget.
CONCLUSIONS: Based on this budget impact analysis, including bimekizumab to the French plaque psoriasis market is expected to substantially reduce productivity losses while keeping the 5-year French health insurance budget unchanged.
METHODS: A 5-year budget impact model was developed to estimate the economic impact of bimekizumab’s introduction into the therapeutic strategy, from a societal perspective. All relevant comparators (anti-tumor necrosis factor (TNF)-alpha, anti-IL-17, anti-IL-12/23, anti-IL-23 and anti-phosphodiesterase (PDE)-4) were included in the analysis. The main market shares uptake assumption was a gain of bimekizumab over anti-IL-17 and anti-IL-23 treatments which have a similar therapeutic class, from 5% in year 1 to 11.6% in year 5. Psoriasis Area and Severity Index (PASI) 100 responses at 52 weeks from a published network meta-analysis, and adverse events incidence from clinical trials and products characteristics were considered. The target population assessed by the French Health Authority was integrated. Direct medical costs were estimated using French databases, including treatment acquisition based on list prices and considering biosimilars when available, administration, monitoring, and adverse events management. Productivity losses were derived from the literature, valued using the mean salary in France and applied to patients not achieving PASI 100.
RESULTS: In the eligible population of 77,350 patients, introducing bimekizumab resulted in total societal cost savings of €35,433,778 over 5 years, mainly driven by a reduction in productivity losses (95%). These savings correspond to a 0.61% decrease in the overall societal expenses associated with plaque psoriasis, estimated at €5,815,046,725. After the first year, annual treatment acquisition costs are reduced by bimekizumab’s inclusion, impacting the health insurance budget.
CONCLUSIONS: Based on this budget impact analysis, including bimekizumab to the French plaque psoriasis market is expected to substantially reduce productivity losses while keeping the 5-year French health insurance budget unchanged.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE348
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis